AstraZeneca, Avillion ‘first-in-class’ combination inhaler shines in Phase 3 trial

An albuterol/budesonide fixed-dose combination rescue medication has been shown to reduce severe exacerbations in patients with asthma for the first time, according to positive Phase 3 trial results announced by AstraZeneca and Avillion.